132 related articles for article (PubMed ID: 18694370)
1. 153Sm: its use in multiple myeloma and report of a clinical experience.
Abruzzese E; Iuliano F; Trawinska MM; Di Maio M
Expert Opin Investig Drugs; 2008 Sep; 17(9):1379-87. PubMed ID: 18694370
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
3. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
4. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
5. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
Kennedy GA; Durrant S; Butler J; Morton J; Western R; Bartlett ML; Allison R; MacFarlane DJ
Leukemia; 2005 May; 19(5):879-80. PubMed ID: 15759033
[No Abstract] [Full Text] [Related]
6. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
[TBL] [Abstract][Full Text] [Related]
7. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
8. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
[TBL] [Abstract][Full Text] [Related]
10. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
[TBL] [Abstract][Full Text] [Related]
11. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
12. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
13. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours.
Milner RJ; Dormehl I; Louw WK; Croft S
J S Afr Vet Assoc; 1998 Mar; 69(1):12-7. PubMed ID: 9646255
[TBL] [Abstract][Full Text] [Related]
14. Biospeciation, by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent.
Charmaine de Witt G; May PM; Webb J; Hefter G
Biometals; 1996 Oct; 9(4):351-61. PubMed ID: 8837456
[TBL] [Abstract][Full Text] [Related]
15. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
[No Abstract] [Full Text] [Related]
16. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
Serafini AN
Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Goel A; Dispenzieri A; Geyer SM; Greiner S; Peng KW; Russell SJ
Blood; 2006 May; 107(10):4063-70. PubMed ID: 16424391
[TBL] [Abstract][Full Text] [Related]
18. Samarium-153 lexidronam for painful bone metastases.
Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
[No Abstract] [Full Text] [Related]
19. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
